Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells.

IntroductionAlthough breast phyllodes tumors are rare, there is no effective therapy other than surgery. Little is known about their tumor biology. A malignant phyllodes tumor contains heterologous stromal elements, and can transform into rhabdomyosarcoma, liposarcoma and osteosarcoma. These versatile properties prompted us to explore their possible relationship to mesenchymal stem cells (MSCs) and to search for the presence of cancer stem cells (CSCs) in phyllodes tumors.MethodsParaffin sections of malignant phyllodes tumors were examined for various markers by immunohistochemical staining. Xenografts of human primary phyllodes tumors were established by injecting freshly isolated tumor cells into the mammary fat pad of non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice. To search for CSCs, xenografted tumor cells were sorted into various subpopulations by flow cytometry and examined for their in vitro mammosphere forming capacity, in vivo tumorigenicity in NOD-SCID mice and their ability to undergo differentiation.ResultsImmunohistochemical analysis revealed the expression of the following 10 markers: CD44, CD29, CD106, CD166, CD105, CD90, disialoganglioside (GD2), CD117, Aldehyde dehydrogenase 1 (ALDH), and Oct-4, and 7 clinically relevant markers (CD10, CD34, p53, p63, Ki-67, Bcl-2, vimentin, and Globo H) in all 51 malignant phyllodes tumors examined, albeit to different extents. Four xenografts were successfully established from human primary phyllodes tumors. In vitro, ALDH+ cells sorted from xenografts displayed approximately 10-fold greater mammosphere-forming capacity than ALDH- cells. GD2+ cells showed a 3.9-fold greater capacity than GD2- cells. ALDH+/GD2+cells displayed 12.8-fold greater mammosphere forming ability than ALDH-/GD2- cells. In vivo, the tumor-initiating frequency of ALDH+/GD2+ cells were up to 33-fold higher than that of ALDH+ cells, with as few as 50 ALDH+/GD2+ cells being sufficient for engraftment. Moreover, we provided the first evidence for the induction of ALDH+/GD2+ cells to differentiate into neural cells of various lineages, along with the observation of neural differentiation in clinical specimens and xenografts of malignant phyllodes tumors. ALDH+ or ALDH+/GD2+ cells could also be induced to differentiate into adipocytes, osteocytes or chondrocytes.ConclusionsOur findings revealed that malignant phyllodes tumors possessed many characteristics of MSC, and their CSCs were enriched in ALDH+ and ALDH+/GD2+ subpopulations

10,13-Dimethyl-16-oxo-4,5,6,7,8,9,10,11,12,13,14,15,16,17-tetra­deca­hydro-1H-cyclo­penta­[a]phenanthren-17-yl acetate

In the title compound, C21H30O3, the five-membered ring adopts an envelope conformation, the cyclo­hexene ring displays a half-chair conformation and the two cyclo­hexane rings have normal chair conformations. In the crystal structure, weak inter­molecular C—H⋯O hydrogen bonding links the mol­ecules into supra­molecular chains running along [100]

Spiniform phase-encoded metagratings entangling arbitrary rational-order orbital angular momentum

Quantum entanglements between integer-order and fractional-order orbital angular momentums (OAMs) have been previously discussed. However, the entangled nature of arbitrary rational-order OAM has long been considered a myth due to the absence of an effective strategy for generating arbitrary rational-order OAM beams. Therefore, we report a single metadevice comprising a bilaterally symmetric grating with an aperture, creating optical beams with dynamically controllable OAM values that are continuously varying over a rational range. Due to its encoded spiniform phase, this novel metagrating enables the production of an average OAM that can be increased without a theoretical limit by embracing distributed singularities, which differs significantly from the classic method of stacking phase singularities using fork gratings. This new method makes it possible to probe the unexplored niche of quantum entanglement between arbitrarily defined OAMs in light, which could lead to the complex manipulation of microparticles, high-dimensional quantum entanglement and optical communication. We show that quantum coincidence based on rational-order OAM-superposition states could give rise to low cross-talks between two different states that have no significant overlap in their spiral spectra. Additionally, future applications in quantum communication and optical micromanipulation may be found

A Novel Surgical Technique: Single-Incision Transumbilical Laparoscopic Roux-en-Y Gastric Bypass

Conventional laparoscopic Roux-en-Y gastric bypass (LRYGB) is a gold standard for bariatric surgery, but the procedure requires five to seven incisions for placement of multiple trocars and thus may produce less-than-ideal cosmetic results. We have developed a new approach, single-incision transumbilical LRYGB (SITU-LRYGB) to treat morbid obesity. We compared the surgical results and patient satisfaction in a study of five-port LRYGB and SITU-LRYGB. Fifty morbidly obese patients (14 males, 36 females) underwent either Roux-en-Y gastric bypass with five-port LRYGB or the SITU-LRYGB approach. During the operation, we used a novel intraoperative liver traction method with a “liver suspension tape” that we specifically designed for SITU-LRYGB. Compared to five-port surgery with SITU-LRYGB, there were no intraoperative complications, wound healing was excellent, and there was no abdominal scarring. SITU surgical time was longer than that with five-port LRYGB (99.8 vs. 67.6 min, P < 0.001). Patients treated with the five-port method were more obese than those in the SITU group (127.9 vs. 112.4 kg, P = 0.016). After the bariatric surgery, no difference in comorbidity was found in both groups. Patient satisfaction was greater with SITU than with the five-port method (4.48 vs. 3.96, P = 0.006). Roux-en-Y gastric bypass can be successfully achieved via a single umbilical incision, a method that provides a short operative time and good recovery and eliminates abdominal scarring

Siamese DETR

Recent self-supervised methods are mainly designed for representation learning with the base model, e.g., ResNets or ViTs. They cannot be easily transferred to DETR, with task-specific Transformer modules. In this work, we present Siamese DETR, a Siamese self-supervised pretraining approach for the Transformer architecture in DETR. We consider learning view-invariant and detection-oriented representations simultaneously through two complementary tasks, i.e., localization and discrimination, in a novel multi-view learning framework. Two self-supervised pretext tasks are designed: (i) Multi-View Region Detection aims at learning to localize regions-of-interest between augmented views of the input, and (ii) Multi-View Semantic Discrimination attempts to improve object-level discrimination for each region. The proposed Siamese DETR achieves state-of-the-art transfer performance on COCO and PASCAL VOC detection using different DETR variants in all setups. Code is available at https://github.com/Zx55/SiameseDETR.Comment: 10 pages, 11 figures. Accepted in CVPR 202

Gene therapy of hypoparathyroidism with TheraCyte-encapsulated stem cells

The parathyroid hormone (PTH) (1-34) gene was inserted into a pcDNA3 promoter and E. coli competent cells were used to amplify the cDNA. C3H/10T1/2 stem cells were transfected with PTH (1-34) cDNA using Lipofectamine reagents. After G418 treatment live cells at a density of 4x107 were loaded onto a TheraCyte unit. After parathyroidectomy, rats were either the implanted with 4x107 TheraCyte-encapsulated cells (group A), subcutaneously injected with 4x107 live cells containing PTH (1-34) cDNA (group B) or injected with nothing (group C).Serum levels of calcium, phosphorus and PTH (1-34) were measured at baseline, 1 month, 2 months, 3 months and 4 months after therapy. Immunohistochemical staining and RT-PCR were performed to find PTH (1-34)-positive cells and to detect PTH (1-34) mRNA.Serum calcium and PTH (1-34) levels were significantly higher in group A than in group B or C. PTH (1-34)-positive cells were found in the TheraCyte group 4 months after implantation. PTH (1-34) mRNA was detected in stem cells 48 hr after transfection and also in stem cells after transfection and 72 hr after G418 treatment.Implantation of the TheraCyte-encapsulated stem cells, which were tranfected with PTH (1-34) cDNA can treat hypoparathyroidism